Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors

被引:19
|
作者
Xu, Caihong [1 ]
Li, Renzhong [1 ]
Shewade, Hemant Deepak [2 ,3 ,4 ]
Jeyashree, Kathiresan [5 ]
Ruan, Yunzhou [1 ]
Zhang, Canyou [1 ]
Wang, Lixia [1 ]
Zhang, Hui [1 ]
机构
[1] China Ctr Dis Control CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China
[2] Int Union TB & Lung Dis, South East Asia Off, New Delhi, India
[3] Int Union TB & Lung Dis, Paris, France
[4] Karuna Trust, Bengaluru, India
[5] Velammal Med Coll Hosp & Res Inst, Madurai, Tamil Nadu, India
来源
PLOS ONE | 2019年 / 14卷 / 04期
关键词
RESISTANT TUBERCULOSIS; DIAGNOSIS; TIME;
D O I
10.1371/journal.pone.0214943
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background China's national tuberculosis programme does not have cohort wise information regarding attrition and delays in the multidrug resistant tuberculosis (MDR-TB) diagnosis and treatment pathway. Objective Under the Global Fund programmatic management of drug-resistant TB (2006-13), we assessed the attrition and delay in the pathway and the factors associated. Methods Cohort study involving secondary programme data. All patients identified as presumptive MDR-TB (defined as i) previously treated TB patients which included recurrent TB, return after loss to follow up, treatment after failure and ii) new TB patients that were non-converters at three months of treatment or in close contact with a known MDR-TB patient) during October 2006 to June 2013 were eligible for phenotypic drug susceptibility testing (DST). Pre-diagnosis attrition (presumptive MDR-TB not undergoing culture and DST) and pretreatment attrition (confirmed MDR-TB patients not initiated on treatment) was calculated. Diagnosis delay was the time interval from DST eligibility to DST result, treatment initiation delay was fom DST result to treatment initiation and total delay was from DST eligbility to treatment initiation. Factors associated with attrition and delay were identified using log binomial regression and linear regression, respectively. Results Of 78 564 presumptive MDR-TB patients, 2 470 (3.1%) underwent pre-diagnosis attrition. Of 9 283 MDR-TB patients, 3 361 (36.2%) underwent pre-treatment attrition. Median(IQR) diagnosis delay was 84 (64, 114) days; treatment initation delay was 23(6,68) days and total delay was 117(77,187) days. Long diagnosis delay was an independent predictor of pretreatment attrition in a dose response relationship. While pre-treatment attrition was less likely among presumptive criterion 'previously treated' and with increasing time period, it was more likey among elderly and in east and west region. While the diagnosis delay increased with time period, treatment initiation delay and total delay reduced with time period. Short diagnosis delay was associated with west region, smear negative patients and presumptive criterion 'treatment after lost to follow up'. Short treatment initiation delay was associatied with east and west regions while long treatment initiation delay was associated with elderly and presumptive criterion 'recurrent TB'. Total delay predictors were similar to treatment initiation delay. In addition, short total delay was associated with presumptive criterion 'treatment after failure'. Conclusion The diagnosis and treatment delay were long and the pre-treatment attrition was considerable high. Long diagnosis delay is likely to predict pre-treatment attrition.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Factors affecting delays in seeking treatment among malaria patients during the pre-certification phase in China
    Lianyu Jia
    Xiaoyu Chen
    Zhanchun Feng
    Shangfeng Tang
    Da Feng
    Malaria Journal, 23
  • [42] Risk of embolic events before and after antibiotic treatment initiation among patients with left-side infective endocarditis
    Matthaios Papadimitriou-Olivgeris
    Benoit Guery
    Nicoleta Ianculescu
    Denise Auberson
    Piergiorgio Tozzi
    Matthias Kirsch
    Pierre Monney
    Infection, 2024, 52 : 117 - 128
  • [43] Risk of embolic events before and after antibiotic treatment initiation among patients with left-side infective endocarditis
    Papadimitriou-Olivgeris, Matthaios
    Guery, Benoit
    Ianculescu, Nicoleta
    Auberson, Denise
    Tozzi, Piergiorgio
    Kirsch, Matthias
    Monney, Pierre
    INFECTION, 2024, 52 (01) : 117 - 128
  • [44] RISK FACTORS FOR TUBERCULOSIS (TB) TREATMENT INTERRUPTION AMONG PATIENTS IN BARINGO COUNTY, KENYA: A RETROSPECTIVE COHORT STUDY
    Yonga, P. O.
    Rutto, K.
    Rono, R.
    Kalya, S. K.
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2019, 113 : S210 - S210
  • [45] Patient, Diagnosis, and Treatment Delays Among Tuberculosis Patients Before and During COVID-19 Epidemic-China, 2018-2022
    Li, Tao
    Du, Xin
    Kang, Jiaojie
    Luo, Dan
    Liu, Xiaoqiu
    Zhao, Yanlin
    CHINA CDC WEEKLY, 2023, 5 (12): : 259 - 265
  • [46] Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China
    Akalu, Temesgen Yihunie
    Clements, Archie C. A.
    Gebreyohannes, Eyob Alemayehu
    Xu, Zuhui
    Bai, Liqiong
    Alene, Kefyalew Addis
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [47] Survival and associated mortality risk factors among post-treatment pulmonary tubercolosis patients in the northwest of China
    Wang, X. -H.
    Ma, A. -G.
    Han, X. -X.
    Liang, H.
    Wang, D.
    Schouten, E.
    Kok, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (11) : 2016 - 2025
  • [48] Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China
    Temesgen Yihunie Akalu
    Archie C. A. Clements
    Eyob Alemayehu Gebreyohannes
    Zuhui Xu
    Liqiong Bai
    Kefyalew Addis Alene
    BMC Infectious Diseases, 24
  • [49] RISK FACTORS FOR LACK OF ANTIVIRAL TREATMENT AMONG CHRONIC HEPATITIS B PATIENTS WHO HAVE DEFINITE AND INDETERMINATE INDICATIONS FOR INITIATION OF THERAPY
    Li, Jia
    Gordon, Stuart C.
    Spradling, Philip R.
    Zhou, Yueren
    Moorman, Anne C.
    Teshale, Eyasu H.
    Boscarino, Joseph
    Schmidt, Mark A.
    Daida, Yihe G.
    Rupp, Loralee B.
    Trudeau, Sheri
    Lu, Mei
    HEPATOLOGY, 2019, 70 : 566A - 567A
  • [50] RISK FACTORS OF SEVERE THROMBOCYTOPENIA FOLLOWING INITIATION OF INTERFERON-BASED THERAPY FOR THE TREATMENT OF HEPATITIS-C AMONG PATIENTS WITH DIAGNOSED CHRONIC LIVER DISEASE
    Lawler, E.
    Altincatal, A.
    Cho, K.
    Grotzinger, K.
    Wang, P.
    Hermos, J.
    Gagnon, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S100 - S101